Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at JP Morgan Healthcare … – Markets Insider
Nasdaq Fortune |
Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at JP Morgan Healthcare …
Markets Insider As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the … Comparing Editas Medicine (EDIT) & OptiNose (OPTN) |
